1028 results for "中国疾控中心2024年12月传染病死亡病例统计数据"

in 6.66 milliseconds.

• BLUEPRINT release August 2016, ChIP-Seq for Acute Promyelocytic Leukemia - MC2392, on genome GRCh38

  ChIP-Seq data for 2 Acute Promyelocytic Leukemia - MC2392 sample(s). 14 run(s), 12 experiment(s), 12 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816

  Dataset EGAD00001002406

• BLUEPRINT release August 2015, ChIP-Seq for plasma cell, on genome GRCh38

  ChIP-Seq data for 2 plasma cell sample(s). 13 run(s), 12 experiment(s), 12 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820

  Dataset EGAD00001001470

• BLUEPRINT release August 2015, ChIP-Seq for neutrophilic metamyelocyte, on genome GRCh38

  ChIP-Seq data for 4 neutrophilic metamyelocyte sample(s). 18 run(s), 12 experiment(s), 12 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820

  Dataset EGAD00001001495

• transcriptomics

  Transcriptomics analysis results

  Dataset EGAD00010001659

• ProteomicAnalysis(DIA)ofmuscleinvasivebladdercancerpatient-derivedxenografts

  Accesstoproteomicfiles(DIA)ofMIBCpatient-derivedxenografts(N=8)

  Dataset EGAD00010002512

• Methylation_gDNA_wbc

  Genome-wide CpG methylation information of genomic DNA samples from white blood cells

  Dataset EGAD00010002586

• HumanCytoSNP12-2-1

  HumanCytoSNP-12 v2.1 on tissue DNA

  Dataset EGAD00010002091

• WGS of 14 paired hepatocellular carcinomas

  Dataset EGAD00001000749

• RNA-seq

  RNA-seq of PDXs

  Dataset EGAD00001001862

• A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers

  This is a phase I clinical trial testing the safety and efficacy of gene-engineered T cells expressing a T-cell receptor targeting an HLA-A*02:01-restricted epitope of HPV-16 E7 (E7 TCR T cells) in patients with metastatic HPV-16+ epithelial cancers. A total of 12 patients were treated. The maximum tested dose was tolerated. Side effects were most consistent with the expected toxicities of the lymphocyte-depleting conditioning regimen and high-dose aldesleukin. Six of the 12 patients demonstrated objective clinical responses. Translational studies of the infused T cell characteristics did not correlate strongly with clinical response. Genomic defects in the targeted peptide-HLA complex did demonstrate definitive mechanisms of resistance in some patients.

  Study phs002286